Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates

Company Performance - Plus Therapeutics reported a quarterly loss of $0.01 per share, outperforming the Zacks Consensus Estimate of a loss of $0.09, and showing improvement from a loss of $0.71 per share a year ago, resulting in an earnings surprise of +88.89% [1] - The company posted revenues of $1.39 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 18.24%, but showing an increase from year-ago revenues of $1.28 million [2] - Over the last four quarters, Plus has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2] Stock Performance - Plus shares have declined approximately 50.1% since the beginning of the year, contrasting with the S&P 500's gain of 10% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $2.21 million, and for the current fiscal year, it is -$0.55 on revenues of $7.16 million [7] Industry Outlook - The Medical - Drugs industry, to which Plus belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]